Skip to contentE
Endonovo Therapeutics, Inc.
E
ENDVEndonovo Therapeutics, Inc. Q1 2022 · 10-Q
Revenue$2.28K$2.28K−93.4% vs Q1 2021 Net Income-$2.41M-$2.41MN/M vs Q1 2021 EPS Diluted-$0.03-$0.03N/M vs Q1 2021 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
Operating Cash Flow-$122,954N/M Margins · derivedGross margin68.7%−24.0 pt vs Q1 2021
Operating margin-21286.7%−19585.8 pt vs Q1 2021
Net margin-105749.7%−98027.2 pt vs Q1 2021
ended Mar 31, 2022 · filed May 19, 2022 · 49 d after period end